Tocilizumab Rechallenge at Reduced Dose Still Triggers Fibrinogen Crash in Arthritis Patient

A striking case report from China has revealed that a widely used rheumatoid arthritis drug can drive a patient’s blood-clotting protein to dangerously low levels twice, even when the dose is slashed by 40 percent. The case, published in Frontiers in Pharmacology, describes a 76-year-old woman whose fibrinogen plummeted after re-exposure to tocilizumab, a monoclonal antibody that blocks the interleukin-6 receptor, and whose clotting protein fell again after a deliberate rechallenge at a substantially reduced dose. The findings carry practical weight for clinicians who must weigh the benefits of this powerful anti-inflammatory agent against an underappreciated hematological risk.

The biology behind this adverse reaction begins with the normal physiology of interleukin-6, a signaling molecule that acts on hepatocytes to drive the acute-phase response. When inflammation flares, IL-6 prompts the liver to ramp up production of fibrinogen, C-reactive protein, and other acute-phase proteins, which is why fibrinogen levels typically rise during active inflammatory states. Tocilizumab interrupts this pathway by binding the IL-6 receptor, and the resulting suppression of hepatic fibrinogen synthesis is generally regarded as a pharmacological effect rather than an idiosyncratic reaction. In most patients this effect is modest and clinically silent, but in a subset the decline is pronounced enough to constitute hypofibrinogenemia, defined in many laboratories as a concentration below 1.5 g/L. The case patient’s pretreatment value of 3.29 g/L sat comfortably within the normal range, and her fall to 0.85 g/L within roughly a month of re-exposure represents a drop of more than seventy percent, a magnitude that would ordinarily raise concern about spontaneous bleeding even though none was observed.

What makes the fibrinogen decline during tocilizumab therapy difficult to interpret at the bedside is that the drug simultaneously suppresses inflammation, which would normally be expected to lower fibrinogen toward baseline rather than below it. The distinction lies in the degree and tempo of the fall. A gradual drift from a mildly elevated value back toward the normal range is expected with effective anti-inflammatory treatment, whereas a steep descent below the reference interval, particularly one that continues after inflammatory markers have already normalized, suggests that IL-6 receptor blockade has unmasked or exaggerated an underlying limitation in fibrinogen production. In this patient, the concurrent laboratory picture offered some reassurance: liver enzymes remained essentially normal at both nadirs, with AST of 24 U/L and ALT of 14 U/L at the first nadir and 29 and 19 U/L at the second, arguing against hepatic synthetic failure as an alternative explanation. Albumin was mildly low at 31.3 g/L, which could reflect chronic disease and inflammation, but the isolated and reproducible nature of the fibrinogen decline, together with its reversal after drug withdrawal, points to a drug-related mechanism rather than a deteriorating liver.

The coagulation profile obtained at the second nadir adds further nuance. Prothrombin time was 11.8 seconds with an international normalized ratio of 0.97, and activated partial thromboplastin time was 21.6 seconds, both within conventional limits. This apparent paradox, in which fibrinogen is markedly reduced yet standard clotting times remain normal, is well recognized. Clotting assays are calibrated against pooled normal plasma, and because fibrinogen is the final common substrate of both the intrinsic and extrinsic pathways, these times often remain preserved until fibrinogen falls to extremely low concentrations, sometimes below 0.5 g/L. Thrombin time, which was prolonged at 25.5 seconds, is more sensitive to fibrinogen availability and can serve as an early clue. The elevated D-dimer of 3,626 μg/L FEU reflects ongoing fibrin turnover, which may be driven by the inflammatory state itself, and complicates the interpretation of fibrinogen dynamics because consumption and impaired production can coexist. Clinicians monitoring patients on tocilizumab therefore cannot rely on routine clotting screens alone and should consider direct fibrinogen measurement when unexplained bruising, mucosal bleeding, or laboratory anomalies appear.

The management decisions in this case illustrate the limited evidence base guiding treatment of tocilizumab-associated hypofibrinogenemia. After the first episode, the team withheld the drug and administered 20 units of cryoprecipitate, a plasma-derived concentrate rich in fibrinogen, factor VIII, von Willebrand factor, and factor XIII. Fibrinogen rose from 0.85 to 1.99 g/L within two days, but the subsequent trajectory, with values of 1.49, 1.85, and 2.07 g/L over the following seven weeks in the absence of further replacement, indicates that endogenous hepatic synthesis recovered once the pharmacological brake was removed. Notably, after the second episode the team chose observation alone, and fibrinogen still climbed from 1.05 to 1.28 g/L and then to 2.45 g/L by late September without any replacement therapy. This spontaneous recovery on both occasions reinforces the view that the effect is reversible and dose-dependent, and it suggests that cryoprecipitate is generally reserved for patients with very low levels or active bleeding rather than administered reflexively.

The question of whether dose reduction can prevent recurrence is central to this report, because it has never been clearly answered in the literature. The patient originally received 400 mg intravenously every four weeks, a dose below the standard 8 mg/kg regimen for her 56 kg body weight, which would have been approximately 448 mg. The rechallenge dose of 240 mg represented a forty percent reduction, yet hypofibrinogenemia still developed, albeit less severely, with a nadir of 1.05 g/L compared with 0.85 g/L during the first episode. The interval to nadir was also compressed, occurring 17 days after re-exposure rather than roughly a month. One plausible interpretation is that the first episode in 2026 was itself a recurrence of an unappreciated effect during the initial treatment course in 2024, when the patient received tocilizumab for about six months. Fibrinogen values recorded that year ranged from 2.21 to 4.36 g/L without a persistent downward pattern, but the available measurements may have been too infrequent to capture transient dips, and the drug was stopped for financial reasons rather than for safety concerns. If true, this would suggest that susceptibility to the effect is a stable individual trait rather than a random event, and that prior tolerance does not guarantee future tolerance.

The patient’s broader clinical context deserves attention because several features may have modulated her risk. She had a 13-year history of seropositive rheumatoid arthritis with high-titer rheumatoid factor and anti-cyclic citrullinated peptide antibodies, coexisting interstitial lung disease that precluded methotrexate, and a treatment history marked by intolerance and complications, including cervical lymph-node tuberculosis during infliximab therapy and a pruritic rash on iguratimod. Intermittent thrombocytopenia predated the 2026 tocilizumab reinitiation and persisted throughout, with platelet counts declining from 60 to 50 × 10^9/L across the observation period. Thrombocytopenia and hypofibrinogenemia together would ordinarily compound bleeding risk, yet the patient remained free of clinically evident bleeding at every stage, which is somewhat reassuring but also reflects the fact that fibrinogen levels above 1.0 g/L are often sufficient for hemostasis in stable patients. A bone marrow examination was considered but deferred because of the bleeding risk associated with severe thrombocytopenia, leaving the platelet decline without a definitive explanation, though chronic inflammation and drug effects are both plausible contributors.

From a surveillance standpoint, the case supports a practical monitoring framework for clinicians using tocilizumab. Because fibrinogen is not part of most standard pre-infusion panels, it may be worth adding to the laboratory schedule for patients beginning therapy, establishing a baseline against which later values can be judged. The timing of the declines in this patient, roughly three to four weeks after infusion in the first episode and just over two weeks after rechallenge, suggests that a check performed midway between infusions would be well positioned to catch a developing nadir before it becomes severe. The absence of bleeding symptoms in both episodes should not breed complacency, since spontaneous hemorrhage becomes a realistic concern once fibrinogen falls below approximately 0.5 to 1.0 g/L, particularly in elderly patients who may have additional vascular fragility or who require anticoagulation for comorbid conditions.

The causality assessment performed by the authors, using both the Naranjo algorithm and the WHO-UMC criteria, yielded a probable rating, which is the highest category typically achievable in the absence of rechallenge data, and the deliberate rechallenge here strengthens the inference considerably. The temporal sequence is clear, the effect reproduced at a lower dose, and alternative explanations such as liver disease, disseminated intravascular coagulation, or consumptive coagulopathy were reasonably excluded by the laboratory findings. The Naranjo algorithm assigns points for previously reported reactions, and hypofibrinogenemia during tocilizumab therapy has indeed been described in case series and real-world cohorts, though the frequency, severity thresholds, and management approaches vary widely across studies. Some real-world analyses suggest the phenomenon is not rare, which raises the question of whether routine fibrinogen monitoring should be considered for all patients on long-term IL-6 blockade rather than only for those with symptoms.

For patients like this woman, whose disease remained highly active with a DAS28 of 5.8 despite prednisone, iguratimod, and Tripterygium wilfordii, the therapeutic options after tocilizumab withdrawal are constrained. Her prior intolerance to iguratimod at higher exposure, her contraindication to methotrexate because of interstitial lung disease, and her adverse experience with a tumor necrosis factor inhibitor narrow the field considerably. Other biologics with different mechanisms, such as B-cell depletion or T-cell costimulation blockade, or targeted synthetic agents, may be considered, each with its own risk profile in a patient with interstitial lung disease and a history of tuberculosis. The decision to rechallenge with tocilizumab at a reduced dose was a reasoned attempt to retain clinical benefit while limiting toxicity, and the improvement in joint symptoms alongside the fall in inflammatory markers, with erythrocyte sedimentation rate dropping from 34 to 10 mm/h and C-reactive protein from 9.05 to 1.21 mg/L, confirms that even the reduced dose retained substantial efficacy. The trade-off, however, was a predictable recurrence of the fibrinogen decline, and the ultimate decision to withhold the drug again reflects the difficulty of balancing disease control against an adverse effect that, while rarely symptomatic in this patient, carries the potential for serious hemorrhagic complications if left unmonitored.

The broader lesson from this report is that hypofibrinogenemia during tocilizumab therapy deserves a place in the differential diagnosis of abnormal coagulation tests in treated patients, and that a prior episode should prompt heightened vigilance rather than reassurance if re-exposure is attempted. Dose reduction, while intuitively appealing, did not prevent recurrence here, and the compressed interval to the second nadir suggests that susceptibility may persist or even intensify with repeated exposure. Until larger datasets clarify which patients are at highest risk and whether any dosing strategy can reliably avoid the effect, individualized monitoring of fibrinogen, particularly in the weeks following initiation or reinitiation, remains the most defensible approach for clinicians managing patients who require this otherwise effective therapy.

Subject of Research: Recurrent tocilizumab-associated hypofibrinogenemia in rheumatoid arthritis after reduced-dose rechallenge

Article Title: Recurrent hypofibrinogenemia after reduced-dose tocilizumab rechallenge in rheumatoid arthritis: a case report

Article References: Li, Y., Yan, Y., Zhou, H., Fu, E., & Zheng, M. (2026). Recurrent hypofibrinogenemia after reduced-dose tocilizumab rechallenge in rheumatoid arthritis: a case report. Frontiers in Pharmacology, 17, 1981054. https://doi.org/10.3389/fphar.2026.1981054

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1981054

Keywords: tocilizumab, hypofibrinogenemia, rheumatoid arthritis, interleukin-6, fibrinogen, drug safety, case report, rechallenge, pharmacovigilance, biologic therapy, coagulation, immunology